Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention

References

• Bosch FX, Ribes J, Morras J. Epidemiology of primary liver cancer. Semin. Liver Dis. 19, 271–286 (1999).
   PubMed Web of Science ®Google Scholar
• ••Review on epidemiology of HCC.
   Google Scholar
• Okuda K. Hepatocellular carcinoma: recent progress. Hepatology15, 948–963 (1992).
   PubMed Web of Science ®Google Scholar
• Sherlock S. Viruses and hepatocellular carcinoma. Gut 35, 828–832 (1994).
   PubMedGoogle Scholar
• Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in western countries. Hepatogastroenterology 45, 1206–1213 (1998).
   PubMedGoogle Scholar
• Donato F, Tagger A, Chiesa R et al. Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a case-control study in Italy. Hepatology26, 579–584 (1997).
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 244, 359–362 (1989).
   PubMed Web of Science ®Google Scholar
• •Discovery of HCV.
   Google Scholar
• Saito I, Miyamura T, Ohbayashi A et al Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Nat/Acad. Li. USA 87, 6547–6549 (1990).
   PubMed Web of Science ®Google Scholar
• ••Clarification of predominant role of HCVinfection in Japanese HCC patients.
   Google Scholar
• Tanaka K, Hirohata T, Koga S eta]. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res. 51,2842–2847 (1991).
   Google Scholar
• Simonetti RG, Camma C, Fiorello F et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann. Intern Med 116, 97–102 (1992).
   PubMed Web of Science ®Google Scholar
• Chuang WL, Chang WY, Lu SN et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. Cancer 69,2052–2054 (1992).
   PubMedGoogle Scholar
• Hwang SJ, Tong M, Lai PPC et al. Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America. Castroenterol Hepato111,949–954 (1996).
   Google Scholar
• Nomura A, Stemmermann GN, Chyou PH, Tabor E. Hepatitis B and C virus serologies among Japanese Americans with hepatocellular carcinoma. J. Infect. Dis. 173, 1474–1476 (1996).
   PubMedGoogle Scholar
• Darby SC, Ewart DW, Giangrande PLF et al Mortality from liver cancer and liver disease in hemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 350,1425–1430 (1997).
   PubMed Web of Science ®Google Scholar
• Gohdse H, Oyefeso A, Kilpatrick B. Mortality of drug addicts in the UK 1967–1993. hit.j Epidemiol 27,473–478 (1998).
   Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl. Med 340,745-750 (1999). Increasing rate of HCC in the USA at present and in future.
   Google Scholar
• Colombo M, de Franchis R, Del Ninno E eta]. Hepatocellular carcinoma in Italian patients with with cirrhosis. N Engl. J. Med. 325, 675–680 (1991).
   Google Scholar
• •Cirrhosis is an important factor for HCC development.
   Google Scholar
• Chiaramonte M, Stroffolini T, Vian A etal. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 85, 2132–2137 (1999).
   Google Scholar
• ••
   Google Scholar
• Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factor for hepatocellular carcinogenesis; a prospective observation of 795 patients with viral and alcoholic cirrhosis. Ilpatology18, 47–53 (1993).
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program in Japan of cirrhotic and non-cirrhotic patients with chronic hepatitis C. Ann. Intern. Med. 131,174-181 (1999).
   Google Scholar
• ••Japanese national survey for inhibition ofHCC development using 2890 patients.
   Google Scholar
• Shiratori Y. Different clinicopathological features of hepatitis B- and C-related hepatocellular carcinoma. J. Gastroenterol Hepatol 11, 942–943 (1996).
   PubMedGoogle Scholar
• Shiratori Y, Shiina S, Imamura M eta]. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 22, 1027–1033 (1995).
   Google Scholar
• •Clinical features of age, gender and underlying liver disese are different between HBV- and HCV-related HCC.
   Google Scholar
• Miyagawa S, Kawasaki S, Makuuchi M. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: Tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology24, 307–310 (1996).
   PubMedGoogle Scholar
• •HCV-related HCC is characterized with multicentricity of tumor nodules.
   Google Scholar
• Sato A, Kato Y, Nakata K et al. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: Comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis. J. Gastroenteml Hepato1.11, 944–948 (1996).
   Google Scholar
• Kew MC, Yu MC, Kedda MA eta]. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 112, 184–187 (1997).
   Google Scholar
• Tanizaki H, Ryu M, Kaman° N et al. Comparison of clinical features and survival in patients with hepatitis B and C virus-related hepatocellular carcinoma. Jpn. Clin. Oncol 27, 67–70 (1997).
   Google Scholar
• Shirabe K, Shimada M, Kajiyama K et al Clinicopathologic features of patients with hepatocellular carcinoma surviving >10 years after hepatic resection. Cancer 83, 2312–2316 (1998).
   Google Scholar
• Chen MC, Jeng LB, Lee WC, Chen TC. Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma. Surgery 123, 554–559 (1998).
   PubMedGoogle Scholar
• Shuto T, Hirohashi K, Kubo S et al Difference of resected hepatocellular carcinoma with hepatitis B or C virus. Hepatogastroentemlogy45, 1722–1725 (1998).
   PubMedGoogle Scholar
• Fasani P, Sangiovanni A, De Fazio C et al High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 29, 1704–1707 (1999).
   PubMedGoogle Scholar
• Tanabe G, Nuruki K, Baba Y et al. A comparison of hepatocellular carcinoma associated with HBV or HCV infection. Hepatogastroentemlogy46, 2442–2446 (1999).
   PubMedGoogle Scholar
• Wu CC, Tang JS, Lin MC eta]. Comparison of liver resection for hepatocellular carcinoma in hepatitis B and hepatitis C-related cirrhotic patients. Hepatogastroentemlogy 46, 651–655 (1999).
   Google Scholar
• Kubo S, Nishiguchi S, Hirohashi K et al. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 86, 793–798 (1999).
   PubMedGoogle Scholar
• Marusawa H, Osaki Y, Kimura T et al. High prevalence of antihepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 45, 284–288 (1999).
   PubMed Web of Science ®Google Scholar
• Chen PJ, Chen DS. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin. Liver Dir. 19, 253–262 (1999).
   PubMedGoogle Scholar
• Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin. Liver Dir. 19, 263–270 (1999).
   PubMedGoogle Scholar
• Tsai JF, Jeng JE, Ho MS et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br. Cancer76, 968–974 (1997).
   Google Scholar
• Donato F, Boffetta P, Puoti M. A meta- analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer 75, 347–354 (1998).
   Google Scholar
• Tagger A, Donato F, Ribero ML et al. Case- control study on hepatitis C virus as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Int. J. Cancer 81, 695–699 (1999).
   PubMedGoogle Scholar
• Tamori A, Nishiguchi S, Kubo S et al. Possible contribution to hepatocarcinogenesis of X transcript of hepatitis B virus in Japanese patients with hepatitis C virus. Hepatology 29, 1429–1434 (1999).
   PubMedGoogle Scholar
• Sugawara Y, Makuuchi M, Takada K. Detection of hepatitis B virus DNA in tissues of hepatocellular carcinomas related to hepatitis C virus which are negative for hepatitis B virus surface antigen. Scand. Gastroenterol 34, 934–938 (1999).
   Google Scholar
• Brechot C, Poucel C, Louise A et al. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 286, 533–535 (1980).
   PubMed Web of Science ®Google Scholar
• Paterlini P, Gerken G, Nakajima E et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl. Med 323, 80–85 (1990).
   PubMed Web of Science ®Google Scholar
• •Integration of HBV DNA in HBs Ag-negative HCC.
   Google Scholar
• Kim CM, Koike K, Saito I et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351, 317–320 (1991).
   PubMed Web of Science ®Google Scholar
• Konayashi S, Saigoh K, Urashima T et al. Detection of hepatitis B virus X transcripts in human hepatocellular carcinoma tissues. I Surg. Res. 73, 97–100 (1997).
   PubMedGoogle Scholar
• Gotllob K, Fulco M, Levero M, Graesssmann A. The hepatitis B virus HBx protein inhibits caspase 3 activity. J. Biol. Chem. 273, 381–385 (1998).
   Google Scholar
• Elmore LW, Hancock AR, Chang et al. Hepatitis B virus X protein and p53 tumor suppressor interaction in the modulation of apoptosis. Proc. Natl Acad. Li. USA 94, 24707–24712 (1997).
   Google Scholar
• Kim H, Lee H, Yum Y. X-gene product of hepatitis B virus induces apoptosis in liver cell. J. Biol. Chem. 273, 381–385 (1998).
   Google Scholar
• Tanaka S, Toh Y, Adachi E et al. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res. 53, 2884–2887 (1993).
   PubMedGoogle Scholar
• Wong N, Lai P, Lee WW et al. Assessment of genetic changes in the hepatocellular carcinoma by comparative genomic hybridization analysis. Am. J. Pathol 154, 37–43 (1999).
   PubMed Web of Science ®Google Scholar
• Oda T, Tsuda H, Hirohashi S et al. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 52, 6358–6364 (1992).
   PubMed Web of Science ®Google Scholar
• Nakamoto Y, Guidotti LG, Kuhhlen CV et al Immune pathogenesis of hepatocellular carcinoma. Exp. Med 188, 341–350 (1998).
   PubMed Web of Science ®Google Scholar
• Tarao K, Ohkawa S, Shimizu A eta]. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from antibody to hepatitis C virus-positive cirrhotic patients. Cancer 73, 1149–1154 (1994).
   Google Scholar
• Moriya K, Fujishiro H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Natum Med. 4,1065–1067 (1998).
   PubMed Web of Science ®Google Scholar
• Ray RB, Steel R, Meywer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J. Biol. Chem. 272, 10983–10986 (1997).
   Google Scholar
• Lo SY, Selby MJ, Ou JH. Interaction between hepatitis C virus core antigen and El envelope protein. J Virol. 70, 5177–5182 (1998).
   Google Scholar
• Ray RN, Lagging LM, Meyer K et al. Transcription regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res. 37, 209–220 (1996).
   Google Scholar
• Ray RB, Steel R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J. Biol. Chem. 272, 10983–10986 (1997).
   Google Scholar
• Kato N, Ono-Nitta S, Lan KH et al. Hepatitis C virus nonstructural region 5A protein is a potent transcription activator. J Viral 71, 8856–8859 (1997).
   PubMedGoogle Scholar
• Kato N, Yoshida H, Ono-Nita SK et al. Activation of intracellular signaling by hepatitis B and C virus: C virus core is the most potent signal inducer. Hepatology 32, 405–412 (2000).
   PubMed Web of Science ®Google Scholar
• Aihara T, Noguchi S, Sasaki Y, Nakano H, Imaoka S. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology107, 1805–1811 (1994).
   Google Scholar
• Tsuda H, Hirohashi S, Shimamoto Y et al. Clonal origin of atypical adenomatous hyperplasia and clonal identity with hepatocellular carcinoma. Gastroenterology 95, 1664–1666 (1988).
   PubMedGoogle Scholar
• Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hpatology28, 953–958 (1998).
   PubMedGoogle Scholar
• Choi BI, Kim TK, Han JK et al. Power versus conventional color Doppler sonography: comparison in the depiction of vasculature in liver tumors. Racliology200, 55–58 (1996).
   Google Scholar
• Koito K, Namieno T, Morita K. Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography. AJR170, 157–161 (1998).
   Google Scholar
• Kudo M, Tomita S, Tochio H et al. Small hepatocellular caicinoma: Diagnosis with US angiography with intraarterial CO2 microbubbles. Radiology182, 155–160 (1992).
   Google Scholar
• Kim TK, Choi BL, Han JK et al. Hepatic tumors: contrast agent-enhancement patterns with pulse-inversion harmonic US. Radiology216, 411–417 (2000).
   PubMedGoogle Scholar
• Ding H, Kudo M, Onda H et al. Contrast- enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. AJR176, 661–666 (2001).
   PubMedGoogle Scholar
• Numata K, Tanaka K, Kiba T et al. Contrast-enhanced, wideband harmonic gray scale imaging of hepatocellular carcinoma: correlation with helical computed tomographic findings. J. Ultrasound Med. 20, 89–98 (2001).
   PubMedGoogle Scholar
• Numata K, Tanaka K, Kiba T et al. Using contrast-enhanced sonography to assess the effectiveness of transcarherter arterial embolization for hepatocellular carcinoma. AJR176, 1199–1205 (2001).
   PubMed Web of Science ®Google Scholar
• Kudo M, Imaging diagnosis of hepatocellular carcinoma and premalignant borderline lesions. Semin. Liver Dis. 19, 297–309 (1999).
   PubMedGoogle Scholar
• •Review article on recent advances in the diagnosis of HCC from the standpoint of hemodynamic of HCC.
   Google Scholar
• Dayton P, Morgan K, Klibanov A et al. Optical and acousticcal observations of the effects of ultrasound on contrast agents. Bans. Ultrason. Fen: Freq. Con. 46, 220–232 (1999).
   Google Scholar
• Coin CG, Chan YS. Computed tomographic arteriography. I Comput. Assist. Tomogr 1, 165–168 (1997).
   Google Scholar
• Hayashi M eta Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR172, 969–976 (1999).
   PubMedGoogle Scholar
• Ueda K, Matsui 0, Kawamori Y et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 206, 161–165 (1998).
   PubMed Web of Science ®Google Scholar
• Shamisi K, Balzer T, Saini S et al Superparamagnetic iron oxide particles (5HU555A): evaluation of efficacy in three doses for hepatic MR imaging. Radiology 206, 365 (1998).
   PubMedGoogle Scholar
• Yamashita Y, Mitsuzaki Y, Yi T et al. Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver. Radiology200, 79–84 (1996).
   PubMedGoogle Scholar
• Oi H, Murakami T, Kim T et al Dynamic MR imaging and earlyphase helical CT for detecting small intrahepatic metastasis of hepatocellular carcinoma. AJR166, 369–374 (1966).
   Google Scholar
• Niwa Y, Matsumura M, Shiratori Y et al. Quantitation of alpha-fetoprotein and albumin messenger RNAs in human hepatocellular carcinoma. Hepatology23, 1384–1392 (1996).
   PubMedGoogle Scholar
• Taketa K, Sekiya C, Namiki M etal. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology99, 508–518 (1990).
   Google Scholar
• Taketa K, Endo Y, Sekiya C et al. A collaborative study for the evaluation of lectin-reactive alfa-fetoprotein in early detection of hepatocellular carcinoma. Cancer Res. 53, 5419–5423 (1993).
   PubMed Web of Science ®Google Scholar
• Van Staden L, Bukofzer S, Kew MC et al. Differential lectin reactivities of alfa-fetoprotein in hepatocellular carcinoma: diagnostic value when serum alfa-fetoprotein levels are slightly raised. J Gastroenterol Hepatol 7, 260–265 (1992).
   PubMedGoogle Scholar
• Yamashita F, Tanaka M, Satomura S et al Prognostic significance of lens culinaris agglutinin A-reactive alfa-fetoprotein in small hepatocellular carcinoma. Gastroenterology111, 996–1001 (1996).
   PubMed Web of Science ®Google Scholar
• •High level of AFP-lectin fraction is associated with poor prognosis of HCC patients.
   Google Scholar
• Kumada T, Nakano S, Kiriyama S et al Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J. Hepatol 30,125–130 (1990).
   Google Scholar
• Takahashi H, Saibara T, Iwamura S et al. Serum alfa-L-fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology 19, 1414–1417 (1994).
   PubMedGoogle Scholar
• Noda K, Miyoshi E, Uozumi N et al. Gene expression of alfal.-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alfa-fetoprotein. Hepatology28, 944–952 (1998).
   Google Scholar
• Aoyagi Y, Isokawa 0, Suda T et al. The fucosylation index of alfa-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer 83, 1078–1082 (1998).
   Google Scholar
• Hayashi K, Kumada T, Nakano S et al.
   Google Scholar
• •• Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am. J. Castroenterol 94,3028-3033 (1999).
   Google Scholar
• Liebman H, Furie BC, Tong MJ. et al. Des- r-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N. Engl. Med. 310,1427–1431 (1984).
   Google Scholar
• Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-r-carboxy) prothrombin. Cancer Res. 49,6493–6497 (1989).
   PubMedGoogle Scholar
• Buienfuis HC, Soute BAM, Vermeer C. Comparison of the vitamin Kl, K2 and K3 as co-factors for the hepatic vitamin K-dependent carboxylase. Biochim. Biophys. Acta 1934,170–175 (1990).
   Google Scholar
• Suttie JW. Recent advances in hepatic vitamin K metabolism and function. Hepatology7, 367–376 (1987).
   PubMed Web of Science ®Google Scholar
• Uehara S, Gotoh K, Handa H eta]. Process of carboxylation of glutamic acid residues in the Gla domain of human des-r-carboxyprothrombin. Clin. Chem. Acta 289,33–44 (1999).
   Google Scholar
• Weintz I, Liebman HA. Des-r-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology18, 990–997 (1993).
   PubMedGoogle Scholar
• Miyakawa T, Kajiwara Y, Shirahata A et al Vitamin K contents in liver tissue of hepatocellular carcinoma patients. Jpn. Cancer Res. 91; 68–74 (2000).
   Google Scholar
• Ishii M, Gama H, Chida N et al. Simultaneous measurements of serum alfa-fetoprotein and protein induced by vitamin A absence for detecting hepatocellular carcinoma. Am. J. Castroenterol 95,1036–1041 (2000).
   PubMedGoogle Scholar
• Izuno K, Fujiyama S, Yamasaki K et al. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-r-carboxy prothrombin and alfa-fetoprotein: a prospective study. Hepatogastroenterology42, 387–393 (1995).
   PubMedGoogle Scholar
• Mita Y, Aoyagi Y, Yanagi M et al The usefulness of determing des-r-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer82, 1643–1648 (1998).
   PubMed Web of Science ®Google Scholar
• Okuda H, Nakanishi T, Takatsu K et al. Serum levels of des-r-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 88,544–549 (2000).
   PubMed Web of Science ®Google Scholar
• Sassa T, Kumada T, Nakano S et al. Clinical utility of simultaneous measurement of serum high-sensitive des-r-carboxy prothrombin and Lens culinaris agglutinin A-reactive alfa-fetoprotein in patients with small hepatocellular carcinoma. Eur. Castroenterol Hepatol 11,1387–1392 (1999).
   PubMedGoogle Scholar
• Shimada M, Takenaka K, Fujiwara Y et al. Des-r-carboxy prothrombin and alfa-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 78, 2094–2100 (1996).
   PubMed Web of Science ®Google Scholar
• Soga K, Watanabe T, Aikawa K et al Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma. Ilpatogastiventemlogy45,1737–1741 (1998).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kashiwagi T, Tsutsumi H et al. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma. Hepatogastroentemlogy46,2464–2468 (1999).
   PubMedGoogle Scholar
• Aoyagi Y, Oguro M, Yanagi M et al. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 77, 1781–1786 (1996).
   PubMedGoogle Scholar
• Hamamura K, Shiratori Y, Shiina S et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-r-carboxy prothrombin and low serum alfa-fetoprotein. Cancer 88,1557–1564 (2000).
   PubMedGoogle Scholar
• Imamura H, Matsuyama Y, Miyagawa Y et al Prognostic significance of anatomical resection and des-r-carboxy prothrombin in patients with hepatocellular carcinoma. BE Surg. 56,1032–1038 (1999).
   Google Scholar
• Khan KN, Yatsuhashi H, Yamasaki K eta]. Prospective analysis of risk factor for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. Hepatol 32,269–278 (2000).
   Google Scholar
• Koike Y, Shiratori Y, Sato S eta]. Des-r-carboxy prothrombin as an useful predisposing factor for development of portal venous invasion of hepatocellular carcinoma. Cancer 91,561–169 (2001).
   Google Scholar
• Ni R, Nishikawa Y, Carr BI. Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation. j Biol. Chem. 273,9906–9911 (1998).
   Google Scholar
• Nishikawa Y, Carr BI, Wang M et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. Biol. Chem. 270,28304–28310 (1995).
   Google Scholar
• Suehiro T, Matsumata T, Itasaka H et al. Des-r-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery117; 682–691 (1995).
   PubMedGoogle Scholar
• Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 22,876–882 (1995).
   PubMed Web of Science ®Google Scholar
• Ebara M, Kita K, Sugiura N eta]. Therapeutic effect of percutaneous ethanol injection on small hepatocellular carcinoma: Evaluation with CT Radiology 195,371–377 (1995).
   Google Scholar
• Shiina S, Imamura M, Omata M. Percutaneous ethanol injection therapy (PEIT) for malignant liver neoplasms. Semin. Intervent. Radiol. 14,295–303 (1997).
   Google Scholar
• Shiina S, Tagawa K, Unuma T et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: a histopathologic study. Cancer68, 1524–1530 (1991).
   PubMed Web of Science ®Google Scholar
• Livraghi T, Bolondi L, Uscarini L et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Hepatol 22,522–526 (1995).
   Google Scholar
• Livraghi T, Giorgio A, Mann G et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197,101-108 (1995). Cohort study to demonstrate the efficacyof PEI using a large number of patients.
   Google Scholar
• Pompili M, Rapacini GL, Luca FD et al. Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer79, 1501–1508 (1997).
   PubMedGoogle Scholar
• Castellano L, Calandra M, Blanco CDV, Sio ID. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection. Analysis of 71 patients. Hepatol 27,862–870 (1997).
   Google Scholar
• Ohnishi K, Yopshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology27,67–72 (1998).
   PubMed Web of Science ®Google Scholar
• Sato M, Watanabe Y, Ueda S et al Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology 110,1507–1514 (1996).
   PubMed Web of Science ®Google Scholar
• Ido K, Isoda N, Kawamoto C eta]. Laparoscopic microwave coagulation therapy for solitary hepatocellular carcinoma performed under laparoscopic ultrasonography. Castrointesi Endosc 41, 68–70 (1995).
   Google Scholar
• Buscarini L, Rossi S, Formari F eta]. Laparoscopic ablation of liver adenoma by radiofrequency electrocauthery. Castrointest. Endsc 41,68–70 (1995).
   Google Scholar
• Rossi 5, Stasi M, Buscarini E et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR167,759–768 (1996).
   Google Scholar
• Solbiati L, Ierace T Goldberg SN et al. Percutaneous US-guided radio-frequency tissue ablation of liver metastasis: treatment and follow-up in 16 patients. Radiology 202,195–203 (1997).
   Google Scholar
• Livraghi T, Goldberg SN, Lazzaroni S et al. Small hepatocellular carcinoma: treatment radio-frequency ablation versus ethanol injection. Radiology210,655–661 (1999).
   PubMed Web of Science ®Google Scholar
• ••Good treatment efficacy of radiofrequencyfor patients with small HCC in a moderate number of patients.
   Google Scholar
• Lencioni R, Caramella D, Bartolozzi C. Hepatocellular carcinoma: use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. Radiology194,113–118 (1995).
   PubMedGoogle Scholar
• Mazzaferro V, Regalia E, Doci R eta]. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl. J. Med. 334,693–699 (1996).
   Google Scholar
• ••Retrospective study to demonstrate a morethan 70% survival at 3 years after liver transplantation for patients with restricted number and size of tumor (3 cm in diameter, less than three nodules).
   Google Scholar
• Michel J, Suc B, Montpeyroux F et al. Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis. J Hepatol 26,1274–1280 (1997).
   Google Scholar
• Figueras J, Jaurrieta E, Valls C eta]. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma. Hepatology25, 1485–1489 (1997).
   Google Scholar
• Colella G, Bottelli R, De Carlis et al. Hepatocellular carcinoma: Comparison between liver transplantation, resective surgery, ethanol injection and chemoembolization. Transplant Int. 11, s193–196 (1998).
   Google Scholar
• Klintmalm GB. Liver transplantation for hepatocellular carcinoma. A registry report of the impact of tumor characteristics on outcome. Ann. Sorg: 228,479-490 (1998).
   Google Scholar
• Otto G, Heuchen U, Hofmann WJ. et al. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma. A retrospective analysis. Ann. Sorg. 227,424–432 (1998).
   Google Scholar
• Marsh JVV, Dvorchick I, Subotin M et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: A pilot study. Hepatology 26,444–450 (1997).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology30,1434–1440 (1999).
   PubMed Web of Science ®Google Scholar
• Sarasin FP, Mentha G, Giostra E, Hadengue A. Partial hepatectomy or liver transplantation for the treatment of resectable hepatocellular carcinoma. A cost-effectiveness perspective. Hepatology 28, 436–442 (1998).
   PubMed Web of Science ®Google Scholar
• Fukutomi Y, Ohmori M, Muto Y et al. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alfa-fetoprotein in human hepatoma-derived cell line. Jpn.j Cancer Res. 81, 1281–1285 (1990).
   PubMedGoogle Scholar
• Nakamura N, Shidoji Y, Yamada Y et al. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line. Biochem. Biophys. Res. Common 207,382–388 (1995).
   PubMedGoogle Scholar
• Moto Y, Moriwaki H, Ninomiyya M et al. Prevention of secondary primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl. Med. 334,1561–1567 (1996).
   PubMedGoogle Scholar
• ••Prospective study to demonstrate theinhibition of newly developing HCC with retinoid analog after resection of primary HCC, although the number was small.
   Google Scholar
• Chang MET, Chen CJ, Lai MS eta]. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J. Med. 336,1855–1859 (1997).
   Google Scholar
• ••Cohort study to demonstrate a reductionof HCC incidence after FIB vaccination in Taiwan.
   Google Scholar
• Niederau C, Heintges T, Lange S et al Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl. J. Med. 334, 1422–1427 (1996).
   PubMed Web of Science ®Google Scholar
• ••Cohort study to demonstrate a beneficial effect of ITN therapy for natural course of hepatitis B patients.
   Google Scholar
• Ikeda K, Saitoh S, Suzuki Y eta]. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. Cancer 82,827–833 (1998).
   Google Scholar
• Lin SM, Sheen ISA, Chien RN, Chu CM, Liaw YE Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29, 971–973 (1999).
   PubMed Web of Science ®Google Scholar
• ••Prospective study to demonstrate aninhibition of HCC development and liver failure in chronic hepatitis B patients with interferon.
   Google Scholar
• Mazzella G, Saracco G, Festi D et al. Long-term results with interferon therapy in chronic type B hepatitis. Am J Castroenterol 94,2246–2250 (1999).
   PubMed Web of Science ®Google Scholar
• Baffis V, Shrier I, Sherker AH, Szllagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann. Intern. Med. 131,696–701 (1999).
   PubMed Web of Science ®Google Scholar
• Omata M, Shiratori Y. Long-term effects of interferon therapy on histological improvement and reduced development of hepatocellular carcinoma in hepatitis C patients. J. Castroenterol Hepatol 15, E134—E140 (2000).
   Google Scholar
• Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis with cirrhosis. Lancet 346,1051–1055 (1995).
   PubMed Web of Science ®Google Scholar
• •Prospective study with a small number of cirrhotic patients to demonstrate inhibition of HCC development.
   Google Scholar
• Mazella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. Hepatol 24,141–147 (1996).
   PubMedGoogle Scholar
• Fattovich G, Giustina G, Degos F et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 27,201–205 (1997).
   PubMed Web of Science ®Google Scholar
• Kuwana K, Ichida T, Kamimura T et al. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J. Castroenterol Hepatol 12,149–155 (1997).
   Google Scholar
• Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 28,1687–1695 (1998).
   PubMed Web of Science ®Google Scholar
• •Prospective study demonstrating natural course of chronic hepatitis C patients.
   Google Scholar
• Serfaty L, Aumatre H, Chazouileres 0 et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology27, 1435–1440 (1998).
   Google Scholar
• International interferon-alfa hepatocellular carcinoma study group. Effect of interferon-a on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet351, 1535–1539 (1998).
   PubMedGoogle Scholar
• •Multicenter retrospective study to clarify the benefitial role of interferon therapy for inhibition of HCC development.
   Google Scholar
• Imai Y, Kawata S, Tamura S eta]. Relation of interferon therapy and hepatocellular carcinoma patients with chronic hepatitis C. Ann. Intern. Merl 129,94–99 (1998).
   Google Scholar
• Kasahara A, Hayashi N, Kochizuki K eta]. Risk factors for hepatocellular and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology27, 1394–1402 (1998).
   Google Scholar
• Ikeda K, Saitoh S, Arase Y, Chayama K et al Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology29,1124–1130 (1999).
   PubMed Web of Science ®Google Scholar
• Olcanoue T, Itoh Y, Minami M et al Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. lipatol 30, 653–659 (1999).
   Google Scholar
• Shindo M, Ken A, Ikuno T Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer85, 1943–1950 (1999).
   PubMedGoogle Scholar
• Shiratori Y, Omata M. Predictors of efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy. How does this modify the treatment course? j Castroenterol Hepatol 15, E141—E151 (2000).
   Google Scholar
• Shiratori Y, Imazeki F, Moriyama M eta]. Histological improvement of fibrosis in hepatitis C patients with sustained response to interferon therapy -long-term follow-up study using paired biopsy samples. Ann. Intern. Merl 132, 517–524 (2000).
   Google Scholar
• •Interferon induces regression of liver fibrosis in sustained responders using more than 500 cases.
   Google Scholar